In English | En español
Questions About Cancer? 1-800-4-CANCER

Find News Releases

Search For:
Between these dates:

All News Releases

Multi-gene test could help spot breast cancer patients most at risk
NCI Cancer Center News
(Posted: 12/12/2013) - A new test has the potential to help physicians identify patients with the most lethal forms of triple-negative breast cancer, a disease which requires aggressive and innovative treatment. The test, whose development was led by researchers from the University of Chicago (home of the University of Chicago Comprehensive Cancer Center) and described in the Dec. 11 issue of PLOS ONE, was able to distinguish between patients with a good or poor prognosis, even within groups of patients already stratified by existing tests such as MammaPrint and Oncotype, as well as to extend its predictions to patients with more advanced or difficult-to-treat cancers.

Gene sequencing project finds family of drugs with promise for treating childhood tumor
NCI Cancer Center News
(Posted: 12/11/2013) - Drugs that enhance a process called oxidative stress were found to kill rhabdomyosarcoma tumor cells growing in the laboratory and possibly bolstered the effectiveness of chemotherapy against this aggressive tumor of muscle and other soft tissue. The findings are the latest from the St. Jude Children’s Research Hospital–Washington University Pediatric Cancer Genome Project and appear in the December 9 edition of the scientific journal Cancer Cell.

Screening decisions must balance potential benefits with potential patient harms
NCI Cancer Center News
(Posted: 12/11/2013) - Screening to detect medical conditions has become standard practice for many diseases, but insufficient attention has been paid to the potential for harm, according to research conducted at the University of North Carolina, including members of its UNC Lineberger Comprehensive Cancer Center. In an article published by the Journal of American Medical Association - Internal Medicine, the authors outline a framework that physicians, patients, policy makers and researchers can use to think systematically about the harms of screening programs. This rationale – a “taxonomy of harms” – makes it easier for decision makers to fully consider all harms to balance against anticipated benefits.

Less painful drug delivery for pediatric leukemia patients is safe, effective
NCI Cancer Center News
(Posted: 12/11/2013) - Children with acute lymphoblastic leukemia (ALL), the most common form of pediatric cancer, can safely receive intravenous infusions of a reformulated mainstay of chemotherapy that has been delivered via painful intramuscular injection for more than 40 years, research from the Dana-Farber Cancer Institute ALL Consortium suggests.

Drug-antibody pair has promising activity in non-Hodgkin lymphoma
NCI Cancer Center News
(Posted: 12/11/2013) - A toxin linked to a targeted monoclonal antibody has shown "compelling" antitumor activity in patients with non-Hodgkin lymphomas who were no longer responding to treatment, according to a report from Dana-Farber Cancer Institute. The ongoing open-label phase 2 study presented at the American Society of Hematology (ASH) meeting was designed to test the activity of brentuximab vedotin (Adcetris) in relapsed or refractory non-Hodgkin lymphoma (NHL) including B-cell cancers such as diffuse large B cell lymphoma (DLBCL).

Potential biological factor contributing to racial disparities in prostate cancer
NCI Cancer Center News
(Posted: 12/09/2013) - Researchers from the Medical University of South Carolina (home of the Hollings Cancer Center) have uncovered a potential biological factor that may contribute to disparities in prostate cancer incidence and mortality between African-American and non-Hispanic white men in the United States, according to results presented at the Sixth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held Dec. 6-9. In the United States, African-American men are 1.5 times more likely to develop prostate cancer and more than twice as likely to die from the disease compared with non-Hispanic white men.

Novel drug regimen can improve stem cell transplantation outcomes
NCI Cancer Center News
(Posted: 12/09/2013) - Adding bortezomib (Velcade) to standard preventive therapy for graft-versus-host-disease (GVHD) results in improved outcomes for patients receiving stem cell transplants from mismatched and unrelated donors, according to researchers from Dana-Farber Cancer Institute. In a new phase 2 trial, patients treated with bortezomib had lower rates of severe acute GVHD and treatment-related mortality, and experienced better one-year overall survival than has been seen historically with such patients receiving standard preventive therapy, the investigators reported at the American Society of Hematology annual meeting.

Novel method could help bring cancer biomarkers to clinic
NCI Cancer Center News
(Posted: 12/09/2013) - An international team of scientists led by a Fred Hutchinson Cancer Research Center cancer proteomics expert has demonstrated the feasibility of large-scale, standardized protein measurements, which are necessary for validation of disease biomarkers and drug targets. The study, published Dec. 8 online in the journal Nature Methods, shows that the scientists' targeted protein-detection approach has the potential to systematically and reliably measure the entire human repertoire of proteins, known as the proteome.

Economic factors may affect getting guideline-recommended breast cancer treatment
NCI Cancer Center News
(Posted: 12/09/2013) - Women with interruptions in health insurance coverage or with low income levels had a significantly increased likelihood of failing to receive breast cancer care that is in concordance with recommended treatment guidelines, according to results presented at the Sixth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held Dec. 6-9. Women with a break in their insurance coverage had a 3.5-fold higher likelihood of nonconcordance with National Comprehensive Cancer Network (NCCN) guidelines for radiation therapy and chemotherapy compared with women with uninterrupted coverage, according to a study from the Fred Hutchinson Cancer Research Center.

Diabetes identified as risk factor for liver cancer across ethnic groups
NCI Cancer Center News
(Posted: 12/09/2013) - Diabetes was associated with an increased risk for developing a type of liver cancer called hepatocellular carcinoma, and this association was highest for Latinos, followed by Hawaiians, African-Americans, and Japanese-Americans, according to results presented by researchers from the Keck School of Medicine of the University of Southern California (home of the USC Norris Comprehensive Cancer Center) at the Sixth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held Dec. 6-9.

< Previous  5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25  Next >